Merck still on the hunt for billion-dollar deals, citing Prometheus and Daiichi Sankyo as examples

Merck is still in pursuit of deals of a similar size and scope to the company’s acquisitions of Prometheus Biosciences and Acceleron, and is willing to pay up to $15 billion.

It’s also still considering smaller deals and collaborations.

During Thursday’s fourth-quarter earnings call, Merck CEO Rob Davis outlined his…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks